Dinutuximab Biosimilar – Anti-ganglioside GD2 mAb – Research Grade

Description of Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb - Research Grade

General information on Anti-ganglioside GD2[Homo sapiens] (Dinutuximab) Monoclonal Antibody

Dinutuximab is ahuman/mouse chimeric monoclonal antibody of isotype IgG1 that targets GD2. GD2 is a disialoganglioside expressed on neuroectodermal tumors, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. By binding to GD2, dinutiximab induces apoptosis and inhibits the proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), to treat childrens with high-risk neuroblastoma.

SDS-PAGE for Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb

Dinutuximab Biosimilar - Anti-ganglioside GD2 mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.